Barrett's Esophagus with Dysplasia Treatment Market Snapshot (2023 to 2033)

The global Barrett's esophagus with dysplasia treatment market is expected to garner a market value of US$ 4.5 million in 2023 and is expected to accumulate a market value of US$ 7.54 million by registering a CAGR of 5.3% in the forecast period 2023 to 2033. The market for Barrett's Esophagus with Dysplasia Treatment registered a CAGR of 3.2% in the historical period 2018 to 2022.

Barrett's Esophagus (BE) is a condition where the lining of the esophagus changes and becomes similar to the lining of the intestine. People with BE have an increased risk of developing esophageal cancer, and dysplasia is a precursor to cancer. Therefore, the management of BE with dysplasia is critical for preventing cancer and improving outcomes for patients.

The treatment options for BE with dysplasia depend on the severity of dysplasia and other factors such as patient age, comorbidities, and patient preferences. The Barrett's esophagus with dysplasia treatment market includes various medical devices and drugs used for endoscopic therapies such as radiofrequency ablation catheters, endoscopic mucosal resection devices, and photodynamic therapy agents. The market also includes surgical instruments used in esophagectomy procedures and drugs used for perioperative care.

Report Attribute Details
Expected Market Value (2023) US$ 4.5 million
Anticipated Forecast Value (2033) US$ 7.54 million
Projected Growth Rate (2023 to 2033) 5.3% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Barrett's Esophagus with Dysplasia Treatment Market Demand Analysis vs. Forecast 2023 to 2033

According to market research and competitive intelligence provider, Future Market Insights- the market for Barrett's esophagus with dysplasia treatment reflected a value CAGR of 3.2% during the historical period, 2018 to 2022. The market is expected to grow in the coming years due to the increasing prevalence of BE with dysplasia, the rising adoption of endoscopic therapies, and the development of new drugs and medical devices. The market is also driven by factors such as increasing awareness of BE and dysplasia, favorable reimbursement policies, and the increasing focus on minimally invasive procedures.

In many countries, healthcare systems and insurance companies are providing favorable reimbursement policies for endoscopic therapies. This has made these treatments more accessible to patients and has contributed to the growth of the market. Barrett's esophagus with dysplasia treatment market is a growing market that includes various treatment options such as surveillance, endoscopic therapies, and surgery. The market is driven by factors such as increasing awareness, favorable reimbursement policies, and the development of new drugs and medical devices. The market for Barrett's esophagus with dysplasia treatment is expected to register a CAGR of 5.3% in the forecast period 2023 to 2033.

Which are Some Prominent Drivers of the Barrett's Esophagus with Dysplasia Treatment Market?

Increasing Prevalence of Barrett's esophagus with dysplasia to push market growth

The increasing prevalence of Barrett's esophagus with dysplasia is expected to drive market growth for treatments and therapies for this condition. Barrett's esophagus is a condition where the cells in the lining of the esophagus change and become abnormal due to repeated exposure to stomach acid. This condition is a known risk factor for esophageal cancer.

The prevalence of Barrett's esophagus with dysplasia is increasing globally, driven by various factors such as obesity, gastroesophageal reflux disease (GERD), and aging populations. The rising incidence of obesity and GERD has been identified as the primary drivers for the increasing prevalence of this condition. As the population ages, the prevalence of Barrett's esophagus with dysplasia is also expected to increase.

As the prevalence of the condition increases, there is likely to be a growing demand for treatments and therapies for Barrett's esophagus with dysplasia. This is expected to drive market growth, as more companies invest in the research and development of new treatments and therapies to address the increasing demand.

Furthermore, the growing awareness of the potential risks associated with Barrett's esophagus with dysplasia is expected to increase the number of patients seeking screening and treatment for the condition. This will further contribute to the growth of the market.

The increasing prevalence of Barrett's esophagus with dysplasia is a significant driver for the growth of the market for treatments and therapies for this condition. The market is expected to continue expanding in the coming years as new treatments become available and more patients seek treatment for this condition.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Faced by Barrett's Esophagus with Dysplasia Treatment Market?

Expensive Cost of Treatment to restrict Market Growth

The cost of treatment for Barrett's esophagus with dysplasia can be high, particularly for advanced cases that require more invasive procedures. This can make it difficult for some patients to afford treatment, which can limit market growth.

Additionally, despite increasing awareness of Barrett's esophagus with dysplasia, there is still a lack of knowledge and understanding about the condition among the general population. This can lead to delays in diagnosis and treatment, which can impact the growth of the market.

Moreover, the regulatory requirements for approval of new treatments for Barrett's esophagus with dysplasia can be stringent, which can limit the number of treatments that make it to market. This can impact the availability of new and innovative treatments for patients.

Region-Wise Insights

How is Barrett's Esophagus with Dysplasia Treatment Market Turning Out in the South & East Asia Region?

Increasing awareness and diagnosis of the condition Shaping Landscape for Barrett's Esophagus with Dysplasia Treatment in South & East Asia

The Barrett's esophagus with dysplasia treatment market in the South and East Asia region is growing, driven by factors such as increasing prevalence of the condition, rising healthcare expenditure, and growing awareness of the potential risks associated with Barrett's esophagus.

In the region, the prevalence of Barrett's esophagus with dysplasia is increasing, particularly in countries such as China and India, where there are high rates of obesity and gastroesophageal reflux disease (GERD). As the population in these countries continues to grow and age, the demand for treatment for Barrett's esophagus with dysplasia is expected to increase.

In addition, there has been a growing focus on improving healthcare infrastructure in the region, which has led to increased investment in the development and adoption of new medical technologies and treatments for Barrett's esophagus with dysplasia. This is expected to drive market growth, as more patients have access to effective treatments and therapies.

Moreover, there has been a growing awareness of the potential risks associated with Barrett's esophagus with dysplasia in the region, which has led to increased screening and diagnosis of the condition. This has helped to increase demand for treatments and therapies, driving market growth.

What are the Factors Boosting the Market for Barrett's Esophagus with Dysplasia Treatment in North America?

Increasing Focus on Technological Advancements Shaping Landscape for Barrett's Esophagus with Dysplasia Treatment in North America

The prevalence of Barrett's esophagus with dysplasia is increasing in North America, driven by factors such as obesity, gastroesophageal reflux disease (GERD), and smoking. As the population continues to age, the demand for treatment for Barrett's esophagus with dysplasia is expected to increase. Due to this, there have been significant advancements in endoscopic technologies and treatments for Barrett's esophagus with dysplasia in North America, including radiofrequency ablation (RFA), cryotherapy, and endoscopic mucosal resection (EMR). These treatments are less invasive than traditional surgical approaches, making them more attractive to patients and healthcare providers.

Furthermore, North America has a strong healthcare infrastructure, with well-trained healthcare providers and access to advanced medical technologies. This has helped to support the development and adoption of new treatments for Barrett's esophagus with dysplasia.

These factors are driving the growth of Barrett's esophagus with dysplasia treatment market in North America. However, there are still challenges facing the market, including high treatment costs and the need for more effective and targeted therapies. Nonetheless, the market is expected to continue growing as new treatments and technologies are developed and as the awareness of Barrett's esophagus with dysplasia continues to increase.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-Wise Insights

By Treatment, Which Segment is Likely to Account for a Significant Share?

Radiofrequency ablation (RFA) segment to hold a significant share and push market growth

Among the different treatments for Barrett's esophagus with dysplasia, radiofrequency ablation (RFA) is expected to account for a significant share of the market.

RFA is a minimally invasive treatment that uses heat energy to destroy abnormal tissue in the esophagus. It has been shown to be highly effective in treating Barrett's esophagus with dysplasia, with a low risk of complications and a high rate of success in eliminating abnormal tissue.

In addition to its effectiveness, RFA is also preferred by patients and healthcare providers because it is less invasive than traditional surgical approaches, such as esophagectomy. Other treatments, such as endoscopic resection, photodynamic therapy, and cryotherapy, have also been used to treat Barrett's esophagus with dysplasia, but they are less commonly used and have limitations in terms of efficacy and safety.

Overall, the increasing adoption of RFA for the treatment of Barrett's esophagus with dysplasia is expected to drive significant growth in this segment of the market. However, there may still be demand for other treatments, particularly in cases where RFA is not appropriate or effective.

By Distribution Channel, Which Segment is Likely to Account for a Significant Share?

Hospital pharmacies segment to hold a significant share and push market growth

Hospital pharmacies play a critical role in the management of Barrett's esophagus with dysplasia, as they are often the first point of contact for patients with Barrett's esophagus with dysplasia. Hospital pharmacies provide access to a wide range of medications and specialized treatment options, including invasive procedures and advanced imaging techniques, which are essential for the management of Barrett's Esophagus with Dysplasia.

In addition, hospital pharmacies have access to a multidisciplinary team of healthcare professionals, including physicians, nurses, and pharmacists, who can collaborate to provide comprehensive care to patients with Barrett's Esophagus with Dysplasia. This team-based approach is critical for the management of Barrett's Esophagus with Dysplasia, as it allows for individualized treatment plans that address the unique needs of each patient

Market Competition

Key players in the market include companies such as Competition Deep Dive, GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., In, AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., Abbott, AbbVie Inc., along with healthcare providers and technology companies among other global players.

  • In August 2022, the American College of Gastroenterology released new guidelines for Barrett's esophagus, which suggest expanding the screening methods beyond endoscopic procedures, increasing the frequency of surveillance for short-segment Barrett's esophagus, and implementing volume criteria for endoscopic therapy centers.
  • These guidelines were developed by a team of researchers from the University of North Carolina at Chapel Hill, and cover the definition and diagnosis of Barrett's esophagus, screenings for esophageal adenocarcinoma, surveillance for known Barrett's esophagus, and medical and endoscopic treatments for Barrett's esophagus and early neoplasia.
  • The authors emphasize that these guidelines should be used as a support for clinical practice and that healthcare providers should take into account patient-specific medical conditions, health status, and preferences to provide patient-centered care.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 4.5 million
Market Value in 2033 US$ 7.54 million
Growth Rate CAGR of 5.3% from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered
  • Distribution Channel
  • Treatment
  • Type
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • United States
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • GSK Plc.
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Cipla Inc.
  • Abbott
  • AbbVie Inc.
Customization Available Upon Request

Key Segments Profiled in the Barrett's Esophagus with Dysplasia Treatment Industry Survey

Type:

  • Low Grade Dysplasia
  • High Grade Dysplasia

Treatment:

  • Endoscopic Resection
  • Radiofrequency Ablation
  • Esophagectomy
  • Photodynamic Therapy
  • Cryotherapy

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the market size in 2023?

The market is valued at US$ 4.5 million in 2023.

How is the historical performance of the market?

From 2018 to 2022, the market registered a CAGR of 3.2%.

What will be the market value in 2033?

The market shall reach US$ 7.54 million in 2033.

What is the CAGR for the market until 2033?

The market will register a 5.3% CAGR until 2033.

What opportunities await the market players?

Growing incidences of barrett’s esophagus with dysplasia will likely provide boost to the market.

Table of Content

1. Executive Summary | Barrett's Esophagus with Dysplasia Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033

        5.3.1. Low Grade Dysplasia

        5.3.2. High Grade Dysplasia

    5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

        6.3.1. Endoscopic Resection

        6.3.2. Radiofrequency Ablation

        6.3.3. Esophagectomy

        6.3.4. Photodynamic Therapy

        6.3.5. Cryotherapy

    6.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033

        7.3.1. Hospital Pharmacy

        7.3.2. Retail Pharmacy

        7.3.3. Online Pharmacy

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. Middle East & Africa

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Type

        9.2.3. By Treatment

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Type

        9.3.3. By Treatment

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Type

        10.2.3. By Treatment

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Type

        10.3.3. By Treatment

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Type

        11.2.3. By Treatment

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Type

        11.3.3. By Treatment

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Type

        12.2.3. By Treatment

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Type

        12.3.3. By Treatment

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Type

        13.2.3. By Treatment

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Type

        13.3.3. By Treatment

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Type

        14.2.3. By Treatment

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Type

        14.3.3. By Treatment

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of MEA

        15.2.2. By Type

        15.2.3. By Treatment

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Type

        15.3.3. By Treatment

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Type

            16.1.2.2. By Treatment

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Type

            16.2.2.2. By Treatment

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Type

            16.3.2.2. By Treatment

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Type

            16.4.2.2. By Treatment

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Type

            16.5.2.2. By Treatment

            16.5.2.3. By Distribution Channel

    16.6. United kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Type

            16.6.2.2. By Treatment

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Type

            16.7.2.2. By Treatment

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Type

            16.8.2.2. By Treatment

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Type

            16.9.2.2. By Treatment

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Type

            16.10.2.2. By Treatment

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Type

            16.11.2.2. By Treatment

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Type

            16.12.2.2. By Treatment

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Type

            16.13.2.2. By Treatment

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Type

            16.14.2.2. By Treatment

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Type

            16.15.2.2. By Treatment

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Type

            16.16.2.2. By Treatment

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Type

            16.17.2.2. By Treatment

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Type

            16.18.2.2. By Treatment

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Type

            16.19.2.2. By Treatment

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Type

            16.20.2.2. By Treatment

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Type

            16.21.2.2. By Treatment

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Type

        17.3.3. By Treatment

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. GlaxoSmithKline plc

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Novartis AG

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Bayer AG

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Eli Lilly and Company

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Merck & Co., Inc.

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. AstraZeneca

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Johnson & Johnson Private Limited

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Cipla Inc.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Abbott

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. AbbVie Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Bronchopulmonary Dysplasia Treatment Market

July 2017

REP-GB-4389

July 2023

313 pages

Healthcare

Gastroesophageal Junction Adenocarcinoma Therapeutics Market

March 2023

REP-GB-16787

301 pages

Healthcare

Gastroesophageal Reflux Disease Therapeutics Market

September 2024

REP-GB-1410

Upcoming

Healthcare

Esophageal Catheters Market

September 2024

REP-GB-10029

Upcoming

Explore Healthcare Insights

View Reports
Future Market Insights

Barrett's Esophagus with Dysplasia Treatment Market